Showing 6191-6200 of 8782 results for "".
- KLOX Technologies Announces European CE Mark Approval for Non-Invasive Acne Vulgaris Producthttps://practicaldermatology.com/news/20131119-klox_technologies_announces_european_ce_mark_approval_for_non-invasive_acne_vulgaris_product/2459411/KLOX Technologies Inc. announced that it has received CE mark approval in Europe for its topical photo-converter gel as a Class IIa Medical Device for the treatment of acne vulgaris, including all severities. The gel is part of the company's LumiCleanse System, a first-in-class,
- Antares Pharma Enters into Promotion and Marketing Agreement with LEO Pharma for Otrexuphttps://practicaldermatology.com/news/20131118-antares_pharma_enters_into_promotion_and_marketing_agreement_with_leo_pharma_for_otrexup/2459413/Antares Pharma, Inc. announced an exclusive agreement with LEO Pharma for the promotion and marketing of Otrexup (methotrexate) to dermatologists for symptomatic c
- MELA Sciences Appoints Rose Crane as President and Chief Executive Officer and a Directorhttps://practicaldermatology.com/news/20131106-mela_sciences_appoints_rose_crane_as_president_and_chief_executive_officer_and_a_director/2459422/MELA Sciences, Inc. (MELA), the medical device company that has developed and is commercializing MelaFind(R), an optical diagnostic device using proprietary technology that enables dermatologists to “see” below the surface of a patient's skin to aid in the diagnosis of melanoma, today announced that
- Suneva Medical Announces Expansion Of Its ReGenica Distribution Partnership With Obagi Medical Productshttps://practicaldermatology.com/news/20131101-suneva_medical_announces_expansion_of_its_regenica_distribution_partnership_with_obagi_medical_product/2459424/Suneva Medical, Inc., recently announced plans to expand its existing partnership with Obagi Medical Products, Inc. Suneva Medical distributes, and is the exclusive licensee for, the full line of ReGenica skincare produ
- Subliminally Exposed to be Presented at Cosmetic Surgery Forumhttps://practicaldermatology.com/news/20131029-subliminally_exposed_to_be_presented_at_cosmetic_surgery_forum/2459426/Based on the New York Times and USA Today best seller, Subliminally Exposed, Dr. Steven Dayan and Valerie Monroe will present at this year's Cosmetic Surgery Fo
- New Stelara Data Show Inhibition Of Joint Destruction In Psoriatic Arthritis Patientshttps://practicaldermatology.com/news/20131029-new_stelara_data_show_inhibition_of_joint_destruction_in_psoriatic_arthritis_patients/2459427/New findings from two integrated Phase III Janssen Research & Development, LLC (Janssen)-sponsored studies showed treatment with ustekinumab (Stelara) resulted in
- Rigel Provides Pipeline Updatehttps://practicaldermatology.com/news/20131024-rigel_provides_pipeline_update/2459429/Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced updates on two of the Company's pipeline products: R333, a topical dermatological JAK/SYK inhibitor, and fostamatinib, an oral SYK inhibitor.
- Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2a Cellulite Study of Collegenase Clostridium Histolyticumhttps://practicaldermatology.com/news/20131024-auxilium_pharmaceuticals_inc_announces_first_patient_dosed_in_phase_2a_cellulite_study_of_collegenase_clostridium_histolyticum/2459430/Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully-integrated specialty biopharmaceutical company, today announced the first patient dosed in its Phase 2a study of collagenase clostridium histolyticum (or "CCH") for the treatment of edematous fibrosclerotic panniculopathy ("EFP"), commonly known
- Novartis Announced Positive Phase III Psoriasis Results for Secukinumabhttps://practicaldermatology.com/news/20131021-novartis_announced_positive_phase_iii_psoriasis_results_for_secukinumab/2459432/Novartis announced results from its head-to-head Phase III FIXTURE study showing secukinumab (AIN457), an interleukin-17A (IL-17A) inhibitor, was significantly superior to etanercept (Enbrel) in moderate-to-severe
- Pfizer Announces Top-Line Results of Two Phase III Clinical Trials Of Tofacitinibhttps://practicaldermatology.com/news/20131021-pfizer_announces_top-line_results_of_two_phase_iii_clinical_trials_of_tofacitinib/2459433/Pfizer, Inc. recently announced top-line results from two Phase III clinical trials of tofacitinib, a novel, oral Janus kinase (JAK) inhibitor that is being investigated for the treatment of adults with moderate-to-severe chro